reason report
recap stronger expect guid still
conserv pt
bottom line remain outperform agil given view
compani hold lead posit environment
chemic food test market also repres solid
organ revenu growth higher estim
street out-performance driven growth across
segment especi biopharma chemical/energi academic/
gov end-market agil guid organ growth next
quarter year believ conserv given
histori guidanc agil beaten guidanc
last quarter price target increas
agil deliv anoth strong quarter come organ
revenu growth beat driven y/i growth chemical/
energi end-market rev y/i food rev
y/i growth academic/gov end-market rev addit
biopharma saw y/i growth compar declin y/i last
quarter top moder comp growth last year due growth
across instrument servic consum small molecul
biopharma note revenu book
quarter delay last quarter even exclud extraordinari
revenu biopharma still grew mid-singl digit
chemical/energi still drive growth chemic energi end-
market return growth straight quarter
driven combin new product offer improv
market condit agil uniqu mix product across ga
chromatographi liquid chromatographi spectroscopi offer
well consum acg appear take share
competitor expect momentum continu next quarter
agil caution cyclic market agil
exposur chemic energi end-market
portfolio lever chemic
china expect grow y/i revenu book earlier
normal china mix agil believ differ
order pattern seen prior lunar new year china grew
upper-teen year agil still expect y/i growth
top tough comp contribut book could
due promot agil ran lc consum
quarter-end given guidanc organ growth total
growth year revis revenu ep
forecast
net debt total capit
price-to-earnings lt ep growth
life scienc tool diagnost
compani inform leerink partner llc research
revenu us million ep exclud item amort intang
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rate agil share outperform price target view agil
posit believ compani hold lead posit environment chemic
food test market around world also repres solid margin expans
opportun near medium term spin-off keysight electron manag
busi becom pure-play life scienc tool lst compani agil
focus deliv adjust oper margin believ
achiev exceed longer term leadership ceo mcmullen agil compet
aggress multipl market deliv solid growth biopharma sale
maintain either posit across end-market includ food
environment chemical/energi emerg market includ china continu
post double-digit growth agil posit capit given sizabl exposur
geographi intuvo product cycl could repres opportun
current under-appreci agil repres compani develop core root
industri chemic electron market year transform life
scienc tool technolog leader diversifi access lead end-market
agil share current trade ev/ebitda slightli life
scienc tool peer group averag
believ ev/ebitda valuat provid best measur agil valu
price target appli premium averag lst group ev/
ebitda multipl result appli ev/ebitda multipl ebitda
estim given number tailwind posit agil better compar
lst peer group continu exposur robust biopharma growth china demand
believ premium warrant sustain
primari risk price target includ
biopharma declin pose greatest risk agil margin expans plan declin
biopharma fund could highli impact agil revenu given revenu lever
biopharma industri believ gener biopharma price risk mute given
elect outcom howev impact regulatori chang could see
biopharma compani becom cautiou spend could impact capit
equip purchas includ agil slowdown biopharma fund would
result downsid risk estim valuat biomolecul forecast ramp
drug market mid-teen believ prolifer drive
use agil mass spectromet character molecul pronounc
slowdown biopharma core growth requir margin expans would
slowdown global budget research could pose downsid risk forecast tighten
budget govern academ fund could result lower revenu rel
estim agil much academ government exposur
competitor nevertheless slowdown academ spend could
headwind plan margin expans assum expect core growth furthermor
restrict global budget could result shift focu strategi growth could
increas oper risk declin government spend could risk downsid
forecast growth nih spend flat low-single-digit
soft demand emerg market could derail growth forecast geopolit risk emerg
market could disrupt oper downsid risk valuat forecast geopolit
risk could also impact agil strategi creat higher barrier entri exist futur
market agil oper numer intern market includ china middl east
europ macroeconom impact chines market could lead declin compani
revenu regul chines polici could also caus restrict oper lead
lower activ china question remain china concern detail
headwind could emerg polici risk
continu volatil energi chemic sector could impact growth agil
consider exposur revenu chemic energi industri agil expect
recoveri next year continu volatil crude oil could result downsid risk
agil expect low-single-digit growth next year volatil oil price could impact
budget next year spend certain countri dictat commod price
would lead lower spend chemic energi
dollar million except per share data
good sold
sg sale
 sale
oper expens sale
compani report leerink partner estim
dollar thousand except ep
estimate
revenu
life scienc appli market
diagnost genom
life scienc appli market
diagnost genom
